Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270316 · ClinicalTrials.gov registry record · Phase 1
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
A Phase 1 study of Fabry Disease, sponsored by UniQure Biopharma B.V..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 8
- Study locations
NCT06270316 is a Phase 1 study of Fabry Disease that is actively recruiting participants, run by UniQure Biopharma B.V.. The registered enrollment target is 12 participants, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT06270316, a Phase 1 study of Fabry Disease, is actively recruiting participants, sponsored by UniQure Biopharma B.V..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 8
- Study locations
Study Summary
The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
Conditions Studied
Interventions
- DRUG AMT-191
Study Locations (8)
Alabama
- The Kirklin Clinic Of university of Alabama Birmingham Hospital - Birmingham
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Minnesota
- MHealth Fairview University of Minnesota Medical Center East Bank - Minneapolis
New York
- NYC Health + Hospitals/Metropolitan - New York
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Utah
- University of Utah, Clinical and Translational Sciences Institute - Salt Lake City
Virginia
- Lysosomal & Rare Disorders Research and Treatment Center, Inc - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06270316
The ClinicalTrials.gov registry entry for NCT06270316 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (98% lower). The listed sponsor is UniQure Biopharma B.V., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 1 intervention - of which AMT-191 is the first listed.
NCT06270316 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Alabama, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06270316 about?
NCT06270316 is a clinical study titled "Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease". The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
What is the current status of trial NCT06270316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-05. Estimated completion is 2031-04-30.
What conditions does trial NCT06270316 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT06270316?
The interventions under investigation include: AMT-191 (DRUG).
Who is sponsoring clinical trial NCT06270316?
This trial is sponsored by UniQure Biopharma B.V., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06270316 being conducted?
This trial has 8 study locations across Alabama, Georgia, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
COMPLETED · Phase 1
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.